HCW Biologics announced it has completed a key deliverable under its license agreement with Wugen, securing the transfer of materials and know-how related to its proprietary cytokine-based molecules. According to the company, this final step solidifies Wugen’s rights to develop and commercialize products derived from the licensed technology.
The company said the agreement, originally signed in December 2019 and amended in 2023, covers the use of specific molecules designed to modulate immune responses in oncology and autoimmune indications. HCW Biologics claims these molecules can enhance the activity of certain cell therapies and may have broader applications in immunotherapy.
Under the terms of the deal, HCW Biologics retains rights to use the licensed molecules in other fields outside of Wugen’s focus areas. The company said the agreement includes potential milestone payments and royalties based on future product development and commercialization.
Hcw Biologics claims that completing the deliverable demonstrates its commitment to strategic partnerships that advance its proprietary platforms into clinical development. The company said it continues to explore additional opportunities to leverage its cytokine-based technologies in various therapeutic areas.
